By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

Open Label Media, the team of one behind Root to Rx, comes a quiz to find out your type of skepticism, plus two free interactive games for telling what's true. Stay in the Room shows you how to disagree without a fight, so when the moment matters, you're ready to have the talk. Got Skepticism? runs any claim through a five-move toolkit to test whether your confidence is earned. All three play in your browser in about two minutes at openlabelmedia.com, and I'd love to see your results on social media.

From Issue 012

Issue 012 documented specific pharmaceutical industry failures. Issue 013 poses the structural comparison: if those failures warrant a high standard of scrutiny, the same standard should apply to the dietary supplement industry, which operates under substantially less regulatory oversight and has equally significant financial motivation.

Most of what people find upsetting or confusing about prescription drug commercials comes from real, documented structure, not random ad-agency choice.

A typical direct-to-consumer (DTC) television spot runs in four phases.

1.     The Before establishes the problem: an actor portraying someone affected by the condition, often shot in muted or isolating tones.

2.     The Bridge introduces the drug itself, its name and its FDA-approved use, frequently alongside a doctor conversation.

3.     The After shifts into an idealized lifestyle sequence, hiking, dinner with friends, playing with grandchildren, meant to visually pair the product with a feeling of health and vitality.

4.     The Warnings, or major statement, closes the ad with the required risk disclosure.

The FDA's rules for this format are more specific than most viewers realize. Every product-claim ad must state at least one FDA-approved use, provide both the brand and generic name of the drug, and present the most significant risks from the drug's official prescribing information, which the FDA reviews and approves before the drug reaches market.

In 1997 the FDA relaxed its broadcast rules to allow adequate provision, meaning a TV or radio ad can direct viewers to a website or phone number for full risk information instead of reading the complete prescribing insert aloud. That single policy change is why the fast-talking warning segment exists in its current form, and it is part of why DTC ad spending rose sharply afterward. Print ads do not get this exemption; they still have to carry a full written summary of adverse effects.

As of a 2023 federal rule (Federal Register 88 FR 80958), the FDA further tightened this requirement: the major statement on risks must now be presented in a clear, conspicuous, and neutral manner in both television and radio formats, specifically to close a loophole where the required warnings could be visually or audibly undercut even while technically present.

It is also worth knowing that not every drug ad you see is the same type. A reminder ad assumes you already know what the drug treats and legally cannot describe its use or risks at all, it can only say the name. A help-seeking ad describes symptoms and encourages you to talk to a doctor without naming any product, and it is regulated by the FTC rather than the FDA precisely because no drug is being promoted. If a company's help-seeking ad slips in a specific drug name, it becomes a product-claim ad and falls back under FDA rules. Knowing which type you are watching is itself a useful skeptic's habit.

Two separate, well-documented psychological effects explain why the warnings section of a drug ad tends to leave viewers unsettled without actually informing them, and a third explains why that unease is what sticks instead of the content.

The distraction effect. Jesse King, a marketing researcher at the University of Montana, spent several years coding hundreds of pharmaceutical ads for a study titled “Look, Puppies! A Visual Content Analysis of Required Risk Statements Embedded in Direct-to-Consumer Pharmaceutical Advertising.” He and his team found that risk statements are reliably paired with unrelated positive imagery, grandparents with grandchildren, couples on beaches, scenic mountains. When the visual changes during the spoken warning, viewers need a moment to reorient, and in that moment they can miss real content. Risk perception runs substantially on feeling rather than fact, so pleasant imagery during the warning measurably suppresses how risky the drug feels, independent of what is actually being said.

 The argument dilution effect. Sivanathan and Kakkar ran six experiments with more than 3,000 U.S. participants, using a real Cymbalta radio ad and a real Lunesta print ad. Their finding, published in Nature Human Behaviour: when an ad's disclosure included both major side effects (stroke, suicidal thoughts) and minor ones (dry mouth, headache), participants rated the drug's overall severity as lower, and the drug as more appealing, than when only the major risks were listed. The minor items mathematically drag down the average impression of how dangerous the drug seems. In other words, a longer list of required disclosures can make a drug look safer, not scarier, which is the opposite of the FDA's original assumption behind the fair balance rule. The same researchers tested a fix: presenting major side effects in bold or red text and minor ones in plain text restored an accurate risk impression without removing any disclosed information.

Why the feeling is what you remember. Health communication research known as fuzzy-trace theory holds that people encode and act on the gist of a risk message, its bottom-line meaning, far more than its verbatim details. That is consistent with the common experience of remembering that a drug ad's warning section felt ominous without being able to recall a single specific side effect afterward. The gist that forms is something like “that sounded bad, but everyone in the ad seemed fine, so I am not sure how worried to be,” and that unresolved gist is the lingering unease, not a failure to pay attention.

Put together: the imagery distracts you while the warning plays, the sheer volume of disclosed risk dilutes your judgment of how serious any one risk is, and whatever survives both of those filters gets stored as a vague bad feeling rather than usable information. None of this means the drug is unsafe or that the ad is lying. It means the format itself, even fully compliant with FDA rules, is not well suited to informing a viewer, which is exactly why reading the actual prescribing information, or asking a pharmacist, matters more than watching the ad twice.

Everything above describes a heavily regulated format that still manages to under-inform. Supplement and wellness advertising starts from a different baseline entirely: there is no equivalent structure to fail to communicate, because there is no equivalent structure required.

Prescription drug advertising falls under FDA jurisdiction. Over-the-counter drug advertising and dietary supplement advertising fall under the FTC instead, whose job is truth-in-advertising enforcement after a claim runs, not pre-market review before it airs. The FDA does not test or approve dietary supplements for safety or efficacy before they reach shelves or a Facebook feed, and it does not review supplement ad claims in advance the way it reviews a drug's prescribing information. A 2022 Consumer Reports survey, cited via a physician-reviewed patient education piece from Texas Health Care, found that a third of Americans incorrectly believe supplements are FDA safety-tested. They aren’t, and the ads aren’t required to correct that misunderstanding.

Supplement marketing instead relies on structure/function claims, phrases like “supports immune health” or “promotes joint comfort,” which require no clinical trial support at all, only a standard disclaimer that the statement has not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent any disease. There is no equivalent of the major statement, no equivalent of adequate provision pointing you to full risk data, because there is no comparable risk disclosure requirement to begin with.

The Dietary Supplement Health and Education Act of 1994 (DSHEA) defines dietary supplements as a distinct regulatory category separate from drugs and food. Key provisions:

Premarket evidence burden: dietary supplement manufacturers are not required to submit safety or efficacy data to FDA before marketing a product. They may not claim the product treats, cures, or prevents a disease (drug claims require NDA approval), but they may make structure/function claims, 'supports immune health,' 'promotes joint comfort', without clinical trial support, provided they include the standard disclaimer that FDA has not evaluated the claim.

Post-market enforcement: FDA can take action to remove a supplement if it can demonstrate the product is unsafe. This reversal of the burden of proof means the evidentiary work falls on the government after the product is already in commerce.

Labeling requirements: supplements must list ingredients, serving size, and percent daily values where established. Third-party testing for label accuracy is not mandatory. In a 2015 investigation, the New York Attorney General's office used DNA testing and reported that only about 21 percent of store-brand herbal supplements it tested contained verifiable DNA from the plant on the label. The testing method was later contested as not validated for processed botanical extracts, but the episode remains a widely cited example of label-versus-content concerns.

FDA-regulated pharmaceuticals must be manufactured under Good Manufacturing Practice (GMP) regulations. GMP covers facility design, equipment qualification, process validation, raw material testing, in-process controls, finished product testing, batch record documentation, and staff training. A GMP audit failure can result in warning letters, import alerts, and consent decrees.

Supplement facilities are also subject to GMP requirements, 21 CFR Part 111, but the supplement GMP regulations are less stringent than pharmaceutical GMP, and enforcement history shows significant variation in compliance across the industry.

Research peptides occupy a third category. Sold as 'for research purposes only, not for human consumption,' they are manufactured in chemical synthesis facilities that operate outside the human-use GMP framework entirely. There is no required batch testing, no required identity verification, no required sterility testing for injectable forms, and no adverse event reporting mechanism. When a consumer injects a research peptide, they’re accepting an unknown purity and potency profile from a facility with no accountability for human outcomes.

Clinically significant drug-supplement interactions are documented in the pharmacology literature. The most widely cited examples:

St. John's Wort: a potent inducer of cytochrome P450 3A4 and P-glycoprotein. Co-administration reduces plasma levels of cyclosporine, antiretrovirals, oral contraceptives, warfarin, and certain antidepressants. The interaction with cyclosporine has resulted in documented organ transplant rejection cases.

Red yeast rice: contains monacolin K, which is chemically identical to lovastatin (a prescription statin). Patients taking red yeast rice alongside a prescription statin may be receiving more statin-equivalent activity than either provider or patient intends. Patients taking red yeast rice and warfarin may experience interactions analogous to statin-warfarin interactions.

Berberine: glucose-lowering activity via AMPK activation, and the effect appears to be glucose-dependent. Across randomized trials, berberine has not been shown to significantly raise the risk of hypoglycemia, even alongside oral diabetes drugs, and we have not found documented cases of a berberine-plus-metformin combination causing a hypoglycemic crisis. Additive glucose-lowering is still biologically plausible, though, particularly in patients whose diabetes is already well-controlled, which is precisely why the combination should be disclosed to the prescribing physician rather than assumed to be harmless. Berberine may also weakly inhibit CYP3A4 and CYP2D6, potentially affecting the metabolism of other drug classes.

Kava: hepatotoxic in a subset of users. FDA issued a consumer advisory in 2002. The interaction with hepatotoxic medications and with alcohol is clinically relevant.

The wellness industry's primary evidence format is the testimonial. Not a randomized controlled trial with hundreds, thousands of data points. Instead, the wellness industry uses the before-and-after photo, the personal transformation story, the influencer's reported experience. This format has specific advantages over clinical trial evidence for selling products, but it is also as they say in the biostatistics world, an n of 1, or a sample size of 1.

Testimonials require no control group. There is no way to know whether the person would have improved anyway, or whether improvement was due to the supplement, another lifestyle change, regression to the mean, or placebo effect.

Testimonials require no adverse event reporting. The person who had a bad experience is unlikely to appear in the influencer's feed.

Testimonials create social proof in a way that forest plots do not. A human face reporting personal experience is more persuasive to most people than a 95% confidence interval.

The Root Room’s Dr. Anecdote character is the personification of this format: a claimed credential (the lab coat), a financial relationship with what he is recommending (affiliate links), and evidence provided exclusively in testimonial form. The Skeptic's Toolkit runs well on his content: Q4 (financial stake), Q8 (how many people, has this been replicated?), Q9 (what do independent experts say?).

Everything above about testimonials applies to any single personal account, whether from a stranger, a friend, or a doctor speaking anecdotally. An influencer endorsement adds several additional problems on top, and they are worth naming individually, because each one is invisible from inside the feed.

1)     The incentive is not aligned with your outcome. A treating physician, whatever else is true about the healthcare system, has a professional and ethical obligation oriented toward your result. An influencer's income from an affiliate link or sponsorship is tied to the sale, full stop, regardless of what happens to you after you buy. That is not a character flaw, it is the structure of the arrangement, and it means the enthusiasm in the post was purchased before you ever saw it.

1)     You are seeing a survivorship-biased sample. People who feel a product worked for them are the ones who make content about it. People who felt nothing, or felt worse, generally do not post a follow-up. Layer an engagement-driven algorithm on top of that, and the platform actively amplifies the most enthusiastic, most confident-sounding accounts over the median experience, which may be unremarkable or negative. What reaches your feed is not a representative sample, it is closer to the best-case outliers, selected twice over, once by who chooses to post and again by what the algorithm chooses to show you.

2)     Parasocial trust bypasses the scrutiny you would apply to a stranger. Audiences extend to a familiar creator roughly the trust they would extend to a friend, even though the relationship is one-directional and, in this context, commercial. That borrowed trust is exactly what short-circuits the critical evaluation someone would normally apply to an unfamiliar person's health claim. The parasocial bond is the product being sold as much as the supplement is.

3)     There is no adverse event system behind it. Prescription drugs have a formal post-market surveillance channel, the FDA Adverse Event Reporting System (FAERS), that clinicians and patients can use to flag a problem, and that data feeds back into labeling and, in serious cases, market withdrawal. Supplements have a comparatively under-used voluntary channel (MedWatch), and a product recommended by an influencer often is not even trackable to a specific batch or a specific reported harm the way a prescription drug is. If it goes wrong, there is frequently no formal mechanism catching it.

None of this requires assuming bad faith on the influencer's part. Many genuinely believe what they are sharing. The point is structural: even a sincere, non-malicious testimonial from someone you trust is still an uncontrolled, unreplicated, survivorship-biased, financially entangled single data point, and no amount of sincerity changes what kind of evidence that is.

S, Source it. Trace the claim to its origin. Who made it, what did they actually say, and if there is a study, who funded it?

I, Identify the study type. A press release is not a study. A result in mice is not a result in humans. An observational study is not a randomized trial.

G, Get the consensus. One paper or one viral post is never the whole picture. What does the weight of evidence in the field actually say?

N, Note the uncertainty. Good science says we do not know yet. A claim with no uncertainty built in is a warning sign.

A, Amplify what is real. Do not stop at pointing out what is wrong. Actively share content that gets it right. Every share is a vote for the information ecosystem we live in.

L, Link to the original. When you share something, attach the source, the actual study or statement, not the headline. Make it easy for the next person to check your work.

A short, practical version of everything above, for the next time either kind of ad plays.

Watching a drug commercial: notice when the visual changes during the warning section, that cut is doing distraction work, not just editing. Notice whether major and minor side effects are read at the same pace and the same tone, real risk does not sound identical to a footnote. And know that you can report a specific ad you believe is misleading directly to the FDA through its Bad Ad Program, a real outreach and reporting channel built for exactly this.

Watching a supplement or wellness ad: look for the four warning signs a supplement claim is overreaching: a celebrity or influencer endorsement standing in for evidence, the undefined phrase “natural ingredients,” a vague reference to unnamed “clinical studies,” and manufactured urgency like a limited-time or call-to-order-only offer. Any one of these should slow you down. Two or more is a strong signal to apply the SIGNAL framework above before buying anything.

Both habits point at the same underlying question: not “did this make me feel something,” but “what kind of evidence is actually in front of me, and who benefits if I do not ask.”

If you work in clinical research or regulatory affairs: the supplement industry's interaction with the clinical trial world is asymmetric. Supplement manufacturers can conduct and publish clinical trials, and some do. The DSHEA framework does not prohibit evidence generation, it just doesn’t require it. When supplement trials are conducted, they’re subject to the same publication bias pressures as pharmaceutical trials, with less regulatory oversight and fewer mandatory registries. When evaluating supplement evidence, apply the same critical appraisal standards used for pharmaceutical evidence: sample size, blinding, randomization, control group, and conflict of interest.

If you’re a patient or patient advocate: the disclosure problem runs in both directions. Your prescribing physician may not ask about supplements. You may not volunteer the information. The pharmacist is frequently the last professional to see the full picture of what you are taking, and the interaction between pharmacist and patient on supplement use is often brief and under-resourced. Bringing a written list of everything you take, to every appointment, with every provider, is the most direct action available to you within the current system. I made one for you, based off what I used at clinical research sites, so that you can give your doctors the full story.

If you are a general reader: 'natural' is a description of origin, not a description of effect. The plants, fungi, and animal products from which supplements are derived contain pharmacologically active compounds, that is why some of them appear to work. Pharmacologically active compounds have dose-dependent effects and potential interactions. The absence of FDA review does not mean the absence of biological activity. It means the biological activity has not been systematically characterized.

Q1: What evidence would actually change my mind about this supplement? If the answer is 'nothing,' that is worth examining.

Q5: Am I applying the same standards to all claims? The standard applied to pharmaceutical skepticism should be applied to supplement claims. 'It worked for me' is an anecdote. It is the same class of evidence whether it is offered for a supplement or a drug.

Q7: Do I want this to be true, or do I want to know what is true? The 'natural is safer' framing is emotionally satisfying and commercially promoted. Wanting it to be true is understandable. Wanting to know what is true requires asking different questions.

Drug commercial structure, FDA required elements, adequate provision (1997), reminder and help-seeking ad categories, and the FDA's list of common drug promotion issues: So BK, Kim PY. Understanding Prescription Drug Advertising. StatPearls [Internet], updated February 27, 2024. PMID 34662034. ncbi.nlm.nih.gov/books/NBK574520/

2023 rule requiring the major statement in a clear, conspicuous, and neutral manner: Federal Register 88 FR 80958, Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format, FDA/HHS, 2023. federalregister.gov/documents/2023/11/21/2023-25428

FDA Bad Ad Program, provider and consumer reporting channel for potentially false or misleading prescription drug promotion. fda.gov/drugs/prescription-drug-advertising-and-promotional-labeling/bad-ad-program. Underlying awareness study: O'Donoghue AC, et al., Awareness of the Food and Drug Administration's Bad Ad Program and Education Regarding Pharmaceutical Advertising: A National Survey of Prescribers in Ambulatory Care Settings, J Health Commun, 2015. PMC7342489

Consumer misperception of FDA's DTC advertising oversight (for example, the belief that only safe medications are allowed to be advertised): Sullivan HW, et al., Consumer understanding of the scope of FDA's prescription drug regulatory oversight: A nationally representative survey, Pharmacoepidemiol Drug Saf, 2020. PMC7325631

Distraction effect in DTC pharmaceutical advertising, positive imagery paired with required risk statements: King J, Koppenhafer L, Madrigal R. Look, Puppies!: A Visual Content Analysis of Required Risk Statements Embedded in Direct-to-Consumer Pharmaceutical Advertising. Journal of Public Policy & Marketing, 2021, Vol 40(1), pp. 45 to 61. DOI 10.1177/0743915619889052. Verified directly against the publisher record (SAGE Journals); this is the primary peer-reviewed source, not a secondhand summary.

Argument dilution effect in DTC drug advertising, full side-effect disclosure (major plus minor) lowers perceived severity and increases drug appeal versus major-only disclosure, tested on real Cymbalta and Lunesta ads, six experiments, 3,059 US participants: Sivanathan N, Kakkar H. The unintended consequences of argument dilution in direct-to-consumer drug advertisements. Nature Human Behaviour, 2017, Vol 1, pp. 797 to 802. DOI 10.1038/s41562-017-0223-1. Verified directly against the publisher record (nature.com), including the full abstract and reference list; this is the primary peer-reviewed source, not a secondhand summary.

Fuzzy-trace theory, gist versus verbatim processing of risk information in medical decision making: Reyna VF, A Theory of Medical Decision Making and Health: Fuzzy Trace Theory, Medical Decision Making, 2008. PMC2617718

Supplement red flags (celebrity endorsement, undefined “natural ingredients,” vague “clinical studies,” manufactured urgency) and the one-third-of-Americans FDA-testing misperception, citing a 2022 Consumer Reports survey: Texas Health Care / Privia Medical Group North Texas, “The World of Health Product Advertising,” physician-reviewed, October 31, 2025. txhealthcare.com/posts/the-world-of-health-product-advertising/. Note: the Consumer Reports figure is relayed secondhand through this article; the original 2022 Consumer Reports report was not independently pulled this session.

Dietary supplement market size: Grand View Research, Dietary Supplements Market Report, 2025 (estimated USD 209.5 billion). grandviewresearch.com/industry-analysis/dietary-supplements-market-report

DSHEA 1994 framework: NIH Office of Dietary Supplements. ods.od.nih.gov/About/DSHEA_Wording.aspx

FDA, Questions and Answers on Dietary Supplements. fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements

Berberine mechanism and evidence (AMPK activation, modest glucose effect, not a GLP-1 receptor agonist): review in PMC. ncbi.nlm.nih.gov/pmc/articles/PMC12735998/

BPC-157 regulatory status: not FDA approved and not on the 503A compounding Bulks List as of July 2026. FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 (free base and acetate) for possible 503A Bulks List inclusion on July 23, 2026 (use FDA evaluated: ulcerative colitis; docket FDA-2025-N-6895). Confirm the outcome if publishing after that date. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

Supplement label accuracy: New York Attorney General investigation using DNA testing, 2015 (method later contested for processed botanicals). ag.ny.gov

Supplement manufacturing standard: 21 CFR Part 111, FDA current Good Manufacturing Practice for dietary supplements. ecfr.gov/current/title-21/part-111

SIGNAL framework: Root to Rx SIGNAL Battlecard (canonical S/I/G/N/A/L).

St. John's Wort and organ transplant rejection (CYP3A4 and P-glycoprotein induction lowers cyclosporine): Ernst, Archives of Surgery, 2002 (systematic review). doi.org/10.1001/archsurg.137.3.316. Supporting case report: Turton-Weeks et al., Progress in Transplantation, 2001. doi.org/10.1177/152692480101100207

Red yeast rice (monacolin K, molecularly identical to lovastatin), rhabdomyolysis when combined with cyclosporine: Prasad et al., Transplantation, 2002. doi.org/10.1097/00007890-200210270-00028. Adverse-event review: Banach and Norata, Current Atherosclerosis Reports, 2023. doi.org/10.1007/s11883-023-01157-4

Berberine, glucose-lowering is glucose-dependent and did not significantly raise hypoglycemia risk across 37 randomized trials (n=3,048): Xie et al., Frontiers in Pharmacology, 2022. doi.org/10.3389/fphar.2022.1015045

Berberine (as goldenseal), weak CYP3A4 and CYP2D6 inhibition at typical doses: Hermann and von Richter, Planta Medica, 2012 (systematic review of herb-drug interactions). doi.org/10.1055/s-0032-1315117

Kava hepatotoxicity and the FDA 2002 consumer advisory on severe liver injury: FDA Consumer Advisory, March 25, 2002; CDC MMWR, Hepatic Toxicity Possibly Associated with Kava-Containing Products, 2002, cdc.gov/mmwr/preview/mmwrhtml/mm5147a1.htm. Mechanism review: Olsen et al., Chemical Research in Toxicology, 2011. doi.org/10.1021/tx100412m

Herbal and dietary supplements account for about 20 percent of drug-induced liver injury cases in the U.S. Drug-Induced Liver Injury Network: Halegoua-DeMarzio and Navarro, Liver International, 2024. doi.org/10.1111/liv.16071